Yazar "Gulbas, Hulya" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim Yok
    Öğe
    Dosimetric Evaluation of Deep Inspiration Breath-Hold Technique for Breast Cancer Radiotherapy: A Single-Center Experience
    (Kare Publ, 2020) Temelli, Oztun; Demirtas, Mehmet; Ugurlu, Berat Tugrul; Pepele, Eda Kaya; Yaprak, Bahaddin; Gulbas, Hulya; Eraslan, Fatma Aysun
    OBJECTIVE To retrospectively evaluate the absorbed doses of organs at risk, such as lungs and the heart of the patients who underwent radiotherapy (RT) using the voluntary deep inspiration breath-hold (vDIBH) technique, and to compare the results with the literature. METHODS In this study, 102 patients who underwent adjuvant RT for the treatment of breast cancer in our clinic between November 2018 and December 2019 were included. A breast and/or chest wall, and/or lymph node RT of 50 Gy in 25 fractions was planned for all patients, and an additional boost of 10 Gy in five fractions was planned for patients requiring an RT boost. The treatment plans included 3DCRT, Field in Field (FIF), IMRT and VMAT approaches. RESULTS In the group undergoing supraclavicular fossa RT, the mean V20Gy was found to be 24.8%, compared to 16% in the group not undergoing supraclavicular fossa RT (p<0.01). In the group undergoing mammaria interna RT, the mean heart dose was 3.1 Gy, compared to 2.1 Gy in the group not undergoing mammaria interna RT (p=0.04). CONCLUSION Respiratory motion control techniques can reduce uncertainties in the target related to respiratory motion. The irradiated volume doses of the ipsilateral lung, heart reduce.
  • Küçük Resim Yok
    Öğe
    Prophylactic cranial irradiation in small cell lung cancer: A single-center experience.
    (Allied Acad, 2017) Temelli, Oztun; Bozdag, Nihal Kaplan; Eraslan, Fatma Aysun; Gulbas, Hulya; Gurocak, Simay; Dikilitas, Mustafa
    Objective: Small-Cell Lung Cancer (SCLC) constitutes about 15% of all lung cancers. It tends to frequently metastasize to the brain. Prophylactic Cranial Irradiation (PCI) is performed, when the penetration of chemotherapeutic agents to brain is insufficient. The aim of this study was to report our single-center experience with PCI in SCLC cases. Methods: We retrospectively reviewed 28 patients with SCLC diagnosed between March 2007 and November 2016. Cranial Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) was performed from all patients to exclude metastasis before PCI. Radiation Therapy (RT) was conducted using two different instruments: a three-dimensional conformal RT-based Linear Accelerator (LINAC) instrument was used until 2013 and an Intensity-Modulated Radiation Therapy (IMRT) thereafter. All patients were treated with a total of 25-36 Gy with fraction doses of 2-2.5 Gy. Overall survival was estimated in all patients. Results: The mean age was 56 (range: 36 to 72) y. Only one of the patients was female, while the remaining patients were all males. Twenty two patients (78.5%) were in limited stage SCLC, while six patients (21.5%) were in the extensive stage. Seventeen patients died, while 11 of them survived. The mean survival was 35 months, while it was 40 months for limited stage and 17 months for extensive stage (p=0.027). One, two, and five-year OS rates were 81.4%, 58%, and 17%, respectively. Four (14%) patients developed brain metastasis during follow-up. Of these patients, two were treated with Whole Brain RT (WBRT), one with Stereotactic RT (SBRT), and the other with best supportive care. Conclusion: Our study results suggest that PCI is a safe, low-toxicity treatment modality used to prevent brain metastases in SCLC cases.